Lixte Biotechnology (NASDAQ:LIXT) Trading Up 13.8% – Here’s What Happened

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) shares were up 13.8% during trading on Monday . The stock traded as high as $4.60 and last traded at $4.45. Approximately 218,605 shares traded hands during mid-day trading, an increase of 69% from the average daily volume of 129,055 shares. The stock had previously closed at $3.91.

Analyst Ratings Changes

Separately, Wall Street Zen raised Lixte Biotechnology to a “hold” rating in a report on Saturday, August 9th.

Lixte Biotechnology Stock Performance

The firm has a fifty day moving average price of $3.47 and a 200 day moving average price of $2.02. The firm has a market capitalization of $20.29 million, a price-to-earnings ratio of -3.45 and a beta of 0.46.

Lixte Biotechnology (NASDAQ:LIXT) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.29) EPS for the quarter.

Hedge Funds Weigh In On Lixte Biotechnology

An institutional investor recently raised its position in Lixte Biotechnology stock. FNY Investment Advisers LLC boosted its position in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) by 172.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,000 shares of the company’s stock after purchasing an additional 67,781 shares during the period. FNY Investment Advisers LLC owned about 3.40% of Lixte Biotechnology worth $129,000 as of its most recent SEC filing. Institutional investors own 5.10% of the company’s stock.

Lixte Biotechnology Company Profile

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.